Organizers of gene-editing meeting blast Chinese study but call for ‘pathway’ to human trials
By Dennis Normile,
Science [cites CGS]
| 11. 29. 2018
HONG KONG, CHINA—An international conference on human gene editing dominated by news of the birth of the world's first genetically engineered babies concluded today with a statement from the organizers that harshly condemned the controversial study. But it did not call for a global moratorium on similar studies, as some scientists had hoped; instead it called for a "translational pathway" that might eventually bring the ethically fraught technology to patients in a responsible way.
The hotly debated study, which apparently resulted in twin baby girls whose genomes were altered in a way that could affect their offspring, came to light on the eve of the second International Summit on Human Genome Editing here. The first summit, held in Washington, D.C., in December 2015, concluded with a statement that specifically said that unless and until safety, efficacy, and ethical and regulatory issues are resolved, "it would be irresponsible to proceed with any clinical use of germline editing," a reference to genetic modifications that can be passed on to the next generation.
But that is exactly what Chinese researcher He Jiankui...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...